Keywords: Bristol-Myers Squibb, R&D pipeline, Earnings forecast, Plavix
Bristol-Myers Squibb’ post-Plavix 2013 EPS forecast to drop to $1.95, but still exceeds expectations; promising R&D pipeline
Article | 05 March 2010
At an investment community meeting yesterday, US drug major Bristol-Myers Squibb provided a business overview highlighting its pipeline and an ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
